Mounjaro Dosing: FDA-Label Range, Titration, and Format

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Mounjaro (tirzepatide) has an FDA-approved dosing structure documented in its product label. This article reports those label-level dosing facts — what doses exist, how the format is administered, and what the titration concept looks like — without prescribing or recommending any specific schedule. Dosing decisions belong with a qualified healthcare provider who knows your full medical history.

FDA-label Mounjaro dosing range

Per the Mounjaro FDA label, 2.5 mg starting dose, with maintenance doses up to 15 mg per week per the current FDA label. Mounjaro is administered as a once-weekly subcutaneous injection. The label specifies a graduated titration concept: starting at the lowest dose to allow the body to adapt to GLP-1 pathway activation, then increasing under prescriber supervision based on tolerability and response.

Why titration matters

Slow titration is the standard clinical approach across the GLP-1 class because gastrointestinal side effects — nausea in particular — are most pronounced during dose escalation. The FDA-label titration schedule is designed to reduce intolerable symptoms while maintaining therapeutic momentum. Skipping or accelerating titration is associated with higher discontinuation rates in real-world data.

What to discuss with your healthcare provider

Dose selection, titration speed, and dose adjustments for Mounjaro are individualized clinical decisions. Topics typically discussed include baseline metabolic status, kidney function, GI history, prior medication tolerability, and the FDA-approved indication for which the prescription is written. Never adjust GLP-1 receptor agonist dosing on your own.

Genetic context for the GLP-1 pathway

Variants in GIPR, GLP1R, and FTO sit upstream of any GLP-1 protocol and shape baseline appetite regulation, satiety signaling, and incretin response. They do not predict response to Mounjaro — but they are part of the broader metabolic context that informs an individualized protocol decision.

PlexusDx offers tirzepatide through its Weight Management Protocols, including Tirzepatide protocol. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in GIPR, GLP1R, and FTO that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: Mounjaro vs Zepbound, What is Mounjaro, Zepbound vs Mounjaro, Buy Mounjaro Online.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Learn more about the PlexusDx Tirzepatide protocol or the oral tirzepatide protocol inside the Weight Management Protocols collection. To start upstream with the genetic context, take the Precision Peptide Genetic Test first.

Frequently Asked Questions

What is the FDA-approved dosing for Mounjaro?

Per the Mounjaro FDA label, 2.5 mg starting dose, with maintenance doses up to 15 mg per week per the current FDA label. The label specifies a graduated titration approach. Specific dose selection and titration speed are individualized clinical decisions. Always follow the schedule your prescriber sets — never adjust GLP-1 dosing on your own.

How is Mounjaro administered?

Mounjaro is administered as a once-weekly subcutaneous injection. The full administration protocol — including timing, storage, and injection-technique guidance where applicable — is in the FDA label and the patient information leaflet that ships with the medication. Your prescriber and pharmacist will walk you through it.

Why does Mounjaro have a titration schedule?

Mounjaro is titrated to reduce gastrointestinal side effects (nausea, vomiting, diarrhea) that are most pronounced during dose escalation. The graduated schedule lets the body adapt to GLP-1 pathway activation and improves tolerability. Real-world data link skipped titration to higher discontinuation rates.

Does genetic testing predict Mounjaro dosing?

No. The Precision Peptide Genetic Test does not predict Mounjaro dose response or titration tolerability. It analyzes pathway-level variants in genes that shape baseline GLP-1 biology — context for the broader protocol conversation with a healthcare provider, not a dose-selection tool.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education